Skip to content
value.today

Pelage Pharmaceuticals, Inc.

Total raised
$151 M
3 rounds on record
Latest round
$120 M
Sep 2025
First round on record
Jun 2023
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Pelage Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2025$120 MNo. 3$50 to $250 million

Pelage Pharmaceuticals, Inc.: Raise no. 3, Sep 2025

Investors in this round

5 investors had bought by the notice of Nov 24, 2025: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$120 M of $120 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christina Edward Weng · Executive Officer
  • Daniel Gil · Executive Officer, Director
  • Nathan Edward Wheeler · Executive Officer
  • William Edward Lowry · Executive Officer, Director
  • Cathy Edward Friedman · Director
  • Richard Edward Heyman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Daniel Gil, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 24, 2025. Read the notice at the SEC.

equitySEC
Aug 2024$14 MNo. 2$10 to $50 million

Pelage Pharmaceuticals, Inc.: Raise no. 2, Aug 2024

Investors in this round

6 investors had bought by the notice of Aug 23, 2024: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$14 M of $14 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel Gil · Executive Officer, Director
  • Heather Edward Christofk · Executive Officer
  • Cathy Edward Friedman · Director
  • William Edward Lowry · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Daniel Gil, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 23, 2024. Read the notice at the SEC.

equitySEC
Jun 2023$17 MNo. 1$10 to $50 million

Pelage Pharmaceuticals, Inc.: Raise no. 1, Jun 2023

Investors in this round

6 investors had bought by the notice of Jun 28, 2023: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$17 M of $17 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel Gil · Executive Officer, Director
  • Heather Edward Christofk · Executive Officer
  • Cathy Edward Friedman · Director
  • William Edward Lowry · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Daniel Gil, Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 28, 2023. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Pelage Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2025).

    SEC Form D · Nov 2025

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Nov 2025

That is all the official record says: Pelage Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Pelage Pharmaceuticals, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 6 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Pelage Pharmaceuticals, Inc.
NameRoleNamed in
Christina Edward WengExecutive officerNov 2025
Daniel GilExecutive officerNov 2025
Nathan Edward WheelerExecutive officerNov 2025
William Edward LowryExecutive officerNov 2025
Heather Edward ChristofkExecutive officerAug 2024
Cathy Edward FriedmanDirectorNov 2025
Daniel GilDirectorNov 2025
Richard Edward HeymanDirectorNov 2025
William Edward LowryDirectorNov 2025